Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ549MR)

This product GTTS-WQ549MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Gastric Cancer, Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ549MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14460MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ854MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ14375MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ4064MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ10667MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ7858MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ14058MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ8044MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA H1H3592P3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW